Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

Diabetes

Volumn 61, Issue 9, 2012, Pages 2340-2348

  Long, S Alice ^a   Rieck, Mary ^a   Sanda, Srinath ^a   Bollyky, Jennifer B ^a   Samuels, Peter L ^a   Goland, Robin ^b   Ahmann, Andrew ^c   Rabinovitch, Alex ^d   Aggarwal, Sudeepta ^e   Phippard, Deborah ^e   Turka, Laurence A ^e,f   Ehlers, Mario R ^g   Bianchine, Peter J ^h   Boyle, Karen D ⁱ   Adah, Steven A ^h   Bluestone, Jeffrey A ^j   Buckner, Jane H ^a   Greenbaum, Carla J ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b Department of Medicine   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH DAKOTA   (United States)

^e Tolerance Assays and Data Analysis Group   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Immune Tolerance Network   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ Rho Federal Systems Division Inc   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; S6 KINASE; STAT5 PROTEIN; SULFAMETHOXAZOLE; TRANSCRIPTION FACTOR FOXP3; TRIMETHOPRIM;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD ANALYSIS; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EFFECTOR CELL; EOSINOPHIL COUNT; EOSINOPHILIA; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MALAISE; MALE; MEMORY CELL; NATURAL KILLER CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET BETA CELL FUNCTION; PANCREAS ISLET CELL FUNCTION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ANIMALS; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HUMANS; INSULIN-SECRETING CELLS; INTERLEUKIN-2; MICE; MICE, INBRED NOD; SIROLIMUS; T-LYMPHOCYTES, REGULATORY;

EID: 84865478468     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0049     Document Type: Article

References (43)

1. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
2. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
3. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
4. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
5. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+) FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-859
6. Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008;7:550-557
7. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009;9:324-337
8. Delgoffe GM, Kole TP, Zheng Y, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009;30:832-844
9. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011;12:295-303
10. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010;33:301-311
11. Monti P, Scirpoli M, Maffi P, et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008;57:2341-2347
12. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008;26: 453-479 (Pubitemid 351600382)
13. Turka LA, Walsh PT. IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. Front Biosci 2008;13:1440-1446
14. Hulme MA, Wasserfall CH, Atkinson MA, Brusko TM. Central role for interleukin-2 in type 1 diabetes. Diabetes 2012;61:14-22
15. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-1878
16. Koulmanda M, Budo E, Bonner-Weir S, et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci USA 2007;104:13074-13079 (Pubitemid 351737595)
17. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008;28:687-697
18. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-2066
19. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-2077
20. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002;51:638-645 (Pubitemid 34760170)
21. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
22. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/ IA-2 autoantibodies. Diabetes 1996;45:926-933 (Pubitemid 26225509)
23. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+) CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010;59: 407-415
24. Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009;69:599-608
25. Sehouli J, Loddenkemper C, Cornu T, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 2011;6:236-246
26. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010;33:826-832
27. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proté gé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378: 487-497
28. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-327
29. Huehn J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 2009;9:83-89
30. Tanemura M, Saga A, Kawamoto K, et al. Rapamycin induces autophagy in islets: relevance in islet transplantation. Transplant Proc 2009;41:334-338
31. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006;55:2429-2436 (Pubitemid 44871142)
32. Piemonti L, Maffi P, Monti L, et al. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011;54:433-439
33. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236-2244 (Pubitemid 44141914)
34. Brauner H, Elemans M, Lemos S, et al. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J Immunol 2010;184:2272-2280
35. Schleinitz N, Vély F, Harlé JR, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010;131:451-458
36. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-5946
37. Bernstein ZP, Porter MM, Gould M, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995;86:3287-3294
38. Hoenstein R, Admon D, Solomon A, Norris A, Moqbel R, Levi-Schaffer F. Interleukin-2 activates human peripheral blood eosinophils. Cell Immunol 2001;210:116-124 (Pubitemid 32835721)
39. Varker KA, Kondadasula SV, Go MR, et al. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Clin Cancer Res 2006;12:5850-5858 (Pubitemid 44629618)
40. Orange JS, Roy-Ghanta S, Mace EM, et al. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest 2011;121:1535-1548
41. Turnquist HR, Cardinal J, Macedo C, et al. mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 2010;115:4758-4769
42. Robb RJ, Kutny RM. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 1987;139:855-862 (Pubitemid 17107088)
43. Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009;182:1541-1547